This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
The U.S. FDA approved Alfuzosin HCL Prolonged Release for neurological disorders on December 30, 2004. Alfuzosin HCL Prolonged Release belongs to the medication class known as alpha-adrenergic antagonist.
Mechanism of Action of undefined
Alfuzosin HCL Prolonged release is categorized as an alpha receptor inhibitor, functioning by specifically obstructing post-synaptic alpha receptors in the smooth muscles of the prostate. This action induces muscle relaxation, facilitating urination by easing the passage of urine.
Uses of undefined
Alfuzosin HCL Prolonged Release is indicated for its use in treating Benign prostatic hyperplasia, a condition that causes enlargement of the prostate gland in men. The prostate gland is located under the urinary bladder; due to excess growth of the prostate gland, the urethra gets suppressed, leading to uncomfortable symptoms like difficulty in urination.
undefined Drug administaration and Dosage available
Take the tablets in the dose and duration prescribed by your physician. Alfuzosin HCL Prolonged release should preferably be taken after meals. Swallow the medication whole with a glass of water. Don't break, crush, or chew the tablet.
Warnings, Precautions and Side Effects of undefined
Warnings
Do not take this medicine if you are allergic to Alfuzosin HCL Prolonged Release or its ingredients. Do not take this medicine if you have liver problems. It is advised that you inform your doctor if you are already taking medicines of the same class, such as their alpha-blockers such as Doxazosin, Indoramin, Prazosin, Terazosin, Tamsulosin, or Phenoxybenzamine to avoid serious complications. Also, if you are taking medication to treat high blood pressure, heart disorders, or fungal infections, report it to your doctor immediately. If you have kidney impairment, birth defects of heartbeat or heart failure, and low blood pressure, talk to your doctor before starting your treatment with Alfuzosin HCL prolonged release.
Precautions
If you are above 65 years old and have been prescribed this tablet, be careful while performing your regular activities, as this tablet might make you more sensitive to developing low blood pressure. While using Alfuzosin HCL Prolonged release, you must notify your doctor about any planned surgical procedures to mitigate the risk of low blood pressure. This is a cancerous condition that commonly affects older men. While on your treatment with this tablet, it is highly unsafe to consume alcohol. Avoid handling machines or driving, as this tablet may cause dizziness and unusual tiredness.
Side Effects
The most common side effects of Alfuzosin HCL Prolonged Release are sleepiness, trouble concentrating, dry mouth, dizziness, increase in appetite, drowsiness, and headache. While taking Alfuzosin HCL Prolonged Release, serious side effects are chest pain and allergic reactions- rashes, swelling, and trouble breathing.
Word Of Advice
Follow the prescribed dosage and administration instructions provided by your healthcare professional. Inform your doctor about any known allergies or medical conditions you have before receiving Alfuzosin HCL Prolonged release. If you notice any unexpected or severe side effects, such as difficulty breathing or an allergic reaction, seek immediate medical attention. Inform your healthcare professional about any other medications or supplements you are consuming to avoid potential drug interactions. If you have any concerns regarding the treatment, consult your healthcare professional for information. Do not take more than prescribed since overdose may cause hypoglycemia (low blood sugar).
Frequently Asked Question
References
- Sanofi, Electronics Medicines Compendium (emc), [ Revised on September 2020] [Accessed on 30th August 2023], https://www.medicines.org.uk/emc/files/pil.1475.pdf
- Sanofi, U.S FDA, [ Revised on September 2013] [Accessed on August 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021287s018lbl.pdf
- KD Tripathi, Essentials of Medical Pharmacology, Antiadrenergic drugs and drugs for glaucoma, 7th edition, 2013, 142.
Disclaimer
The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.